Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics develops targeted genetic medicines for cancer using systemically delivered virotherapy. Its RedTail platform is designed to selectively target tumors, remodel the tumor microenvironment, and express therapeutic genetic payloads at tumor sites while limiting peripheral exposure.
Recurring CLDI news covers RedTail research presentations, CLD-401 oncology data, IL-15 superagonist payload work, in situ T-cell engager approaches, regulatory preparation, manufacturing and clinical-development partnerships, financing activity, and periodic financial results. Company updates also address pipeline expansion, including RedTail-based programs such as CLD-501 for TROP2-targeted T-cell engagement in solid tumors.
Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company's innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.
The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI) issued a shareholder letter highlighting significant company developments under new CEO Eric Poma. The company's primary focus is advancing their RedTail platform, a systemic virotherapy platform for delivering genetic medicines to metastatic cancer sites.
Key developments include the appointment of Dr. Guy Travis Clifton as CMO, positive preclinical data presentations at AACR and ASCO meetings, and plans for an IND filing by end of 2026 for CLD-401, their lead RedTail candidate. The company also opened an IND for SuperNova virotherapy (CLD-201) with phase I trials expected to start by end of 2025.
Financially, Calidi reported $10.6 million in cash at Q1 2025 end, with reduced costs and lower burn rate. The company has retired most of its debt and is exploring partnership opportunities with leading biopharmaceutical companies.
Calidi Biotherapeutics (NYSE: CLDI) has announced IL15 superagonist as the first payload for its systemic antitumor virotherapy platform, RTNova. The announcement was made at the AACR Annual Meeting on April 27, 2025.
The RTNova platform utilizes an engineered vaccinia virus designed for tumor-selective targeting and produced in an enveloped form that enables survival in bloodstream circulation to reach metastatic tumor sites. Preclinical data demonstrates that the platform's ability to express IL15 superagonist specifically in tumor microenvironments significantly increases complete tumor elimination responses after a single systemic administration.
This advancement represents a significant step in treating metastatic cancers, as it overcomes the limitations of traditional intratumoral oncolytic viruses by enabling systemic administration. The platform can also be adapted to deliver various therapeutic payloads, allowing customized treatment approaches for different tumor types.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has granted an inducement non-qualified stock option to its newly appointed CEO, Eric Poma, Ph.D. The stock option allows for the purchase of 726,412 shares at an exercise price of $0.469 per share, based on the closing price on April 22, 2025.
The stock options feature a four-year vesting schedule, with 25% vesting on April 22, 2026, and the remaining portion vesting in equal monthly installments through April 22, 2029. This grant was approved by the Company's Compensation Committee and Board of Directors in accordance with Section 711 of NYSE American Company Guide.
Calidi Biotherapeutics (NYSE American: CLDI) has announced a significant leadership transition, with Eric Poma, Ph.D. succeeding Allan Camaisa as CEO and Board Director, effective April 22, 2025. Camaisa will remain on the Board.
Dr. Poma brings over 30 years of biopharmaceutical industry experience, notably as CEO of Molecular Templates where he raised $250+ million in equity financing and secured $150+ million through strategic agreements with Takeda, Vertex, and BMS. His background includes roles at Innovive Pharmaceuticals, Imclone Systems, and as a Healthcare & Biotechnology Analyst.
The transition comes as Calidi, a clinical-stage biotechnology company, advances its systemic enveloped virotherapy platform, including preparations for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company continues development of its CLD-400, CLD-101, and CLD-201 programs.
Calidi Biotherapeutics (NYSE American: CLDI) announces an exclusive live investor webinar scheduled for April 24, 2025, at 4:15 p.m. ET. The event will feature presentations by newly appointed Chief Medical Officer Dr. Guy Travis Clifton and CFO Andrew Jackson.
Dr. Clifton, a surgical oncologist and U.S. Army Colonel with 17 years of experience in oncology drug development, will discuss Calidi's stem cell-based delivery platforms for enhanced cancer treatment. The webinar will highlight the company's progression following FDA clearance of their IND application for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, focusing on breast cancer, head & neck cancer, and soft tissue sarcoma.
The presentation will also cover other lead programs including CLD-400 (RTNova) for metastatic and lung cancer, and CLD-101 for high-grade gliomas. A Q&A session will follow the presentation.
Calidi Biotherapeutics (NYSE American: CLDI) has received FDA clearance for its Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors in adults. The therapy will focus on treating breast cancer, head & neck cancer, and soft tissue sarcoma.
The IND application included preclinical data showing CLD-201's potential to evade viral inactivation by the patient's immune system and effectively target cancer cells. The innovative treatment combines adipose tissue-derived stem cells with oncolytic vaccinia virus, representing a unique approach in cancer therapy.
Upcoming clinical trials will evaluate the safety, tolerability, and preliminary efficacy of CLD-201 in patients with these difficult-to-treat tumors, addressing significant unmet medical needs.
Calidi Biotherapeutics (NYSE: CLDI) has appointed Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. This announcement comes as the company advances its targeted antitumor virotherapies through clinical development.
Dr. Clifton brings over 17 years of experience in drug development, early phase trials, and cancer immunotherapy. He previously served as CMO at Parthenon Therapeutics/Incendia Therapeutics and has been a practicing surgical oncologist in the US Army since 2013. His expertise includes advising over 20 companies and authoring more than 80 peer-reviewed publications.
The appointment aligns with Calidi's recent IND filing for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company is developing two platforms: a systemic approach using extracellular enveloped viruses to target metastatic tumors, and an intratumoral approach using stem cells to protect and enhance virotherapy potency.